[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UA117218C2 - Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f - Google Patents

Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f

Info

Publication number
UA117218C2
UA117218C2 UAA201314154A UAA201314154A UA117218C2 UA 117218 C2 UA117218 C2 UA 117218C2 UA A201314154 A UAA201314154 A UA A201314154A UA A201314154 A UAA201314154 A UA A201314154A UA 117218 C2 UA117218 C2 UA 117218C2
Authority
UA
Ukraine
Prior art keywords
polypeptide against
polypeptide
psoriasis
asthma
arthritis
Prior art date
Application number
UAA201314154A
Other languages
English (en)
Inventor
Хейді Роммеларе
Йоост Александер Колкман
Майкл Джон Скотт САУНДЕРС
Анн Юніан
Йоланде Швачко
Аманда Е.І. Проудфот
Алєн Вікарі
Дені Брюнікєль
Лоран Шевалє
Олів'є Лєгер
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46245559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA117218(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of UA117218C2 publication Critical patent/UA117218C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Винахід стосується полінуклеотиду, спрямованого проти IL-17A, IL-17F та/або IL-17A/F, фармацевтичної композиції, що містить зазначений поліпептид, застосування такого пептиду для лікування або профілактики артриту, розсіяного склерозу, псоріазу та астми.
UAA201314154A 2011-05-05 2012-04-05 Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f UA117218C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161482802P 2011-05-05 2011-05-05
PCT/EP2012/058313 WO2012156219A1 (en) 2011-05-05 2012-05-04 Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same

Publications (1)

Publication Number Publication Date
UA117218C2 true UA117218C2 (uk) 2018-07-10

Family

ID=46245559

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201314154A UA117218C2 (uk) 2011-05-05 2012-04-05 Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f

Country Status (25)

Country Link
US (4) US10017568B2 (uk)
EP (3) EP3363815A1 (uk)
JP (5) JP6628965B2 (uk)
KR (1) KR102083230B1 (uk)
CN (2) CN107098971B (uk)
AU (1) AU2012257942B8 (uk)
BR (1) BR112013028407B1 (uk)
CA (1) CA2834907C (uk)
CL (1) CL2013003090A1 (uk)
DK (1) DK2705058T3 (uk)
EA (1) EA035973B9 (uk)
ES (1) ES2662371T3 (uk)
HR (1) HRP20180380T1 (uk)
HU (1) HUE037225T2 (uk)
IL (1) IL228813B (uk)
LT (1) LT2705058T (uk)
MX (1) MX2013012844A (uk)
MY (1) MY167231A (uk)
NZ (1) NZ616761A (uk)
PH (1) PH12013502234A1 (uk)
PT (1) PT2705058T (uk)
SG (2) SG194632A1 (uk)
SI (1) SI2705058T1 (uk)
UA (1) UA117218C2 (uk)
WO (1) WO2012156219A1 (uk)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2791951C (en) 2010-05-20 2019-05-14 Ablynx Nv Biological materials related to her3
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
US10526384B2 (en) 2012-11-19 2020-01-07 Pieris Pharmaceuticals Gmbh Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof
FR3007411B1 (fr) * 2013-06-21 2015-07-03 Agronomique Inst Nat Rech Anticorps monocatenaire a chaine lourde de camelide dirige contre la chromatine et utilisations
BR112016018980A2 (pt) 2014-02-21 2017-10-10 Genentech Inc método de tratamento de um distúrbio, anticorpo multiespecífico, ácido nucleico isolado, célula hospedeira, métodos de produzir um anticorpo, de produção de uma metade de anticorpo ou de um anticorpo multiespecífico e de produção de um anticorpo multiespecífico, imunoconjugado e formulação farmacêutica
BR112016026773A2 (pt) 2014-05-16 2017-12-12 Ablynx Nv domínios variáveis de imunoglobulina aperfeiçoados
ES2823563T3 (es) * 2014-05-22 2021-05-07 Pieris Pharmaceuticals Gmbh Polipéptidos de unión específica novedosos y usos de los mismos
US20160000936A1 (en) 2014-06-10 2016-01-07 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
RU2609627C2 (ru) * 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
GB201500463D0 (en) * 2015-01-12 2015-02-25 Cresendo Biolog Ltd Therapeutic molecules
EP3247407A4 (en) 2015-01-21 2018-08-22 Inhibrx LP Non-immunogenic single domain antibodies
WO2016123329A2 (en) 2015-01-28 2016-08-04 Genentech, Inc. Gene expression markers and treatment of multiple sclerosis
EP3368570A1 (en) * 2015-10-27 2018-09-05 UCB Biopharma SPRL Methods of treatment using anti-il-17a/f antibodies
GB201522391D0 (en) * 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibody molecules
RU2680011C2 (ru) * 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
GB201612043D0 (en) * 2016-07-11 2016-08-24 Crescendo Biologics Ltd Composition for treatment of disorders
AU2018217816A1 (en) 2017-02-10 2019-08-15 Genentech, Inc. Anti-tryptase antibodies, compositions thereof, and uses thereof
CN108359011B (zh) * 2017-07-21 2019-06-25 华博生物医药技术（上海）有限公司 靶向于白介素17a的抗体、其制备方法和应用
CN107857818A (zh) * 2017-08-07 2018-03-30 上海科新生物技术股份有限公司 一种针对IL‑17和TNF‑α的双特异性融合蛋白
CN113603777B (zh) * 2018-02-12 2022-10-21 原启生物科技(上海)有限责任公司 Il17抗体及其应用
CN110003329B (zh) * 2019-04-12 2022-09-27 深圳普瑞金生物药业股份有限公司 多肽、il17a/f单域抗体、核苷酸序列及试剂盒
WO2022012636A1 (en) * 2020-07-15 2022-01-20 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric il17a and/or il17f
US20230416942A1 (en) * 2020-08-21 2023-12-28 Yale University Nanobody Compositions and Methods of Use of the Same
WO2023035272A1 (zh) * 2021-09-13 2023-03-16 深圳华普药物研发有限公司 一种il17抗体及其制备方法和应用
CN114380906B (zh) * 2022-03-25 2022-06-14 南京融捷康生物科技有限公司 一种抗il-17a的单域抗体及其用途
WO2023186174A1 (en) * 2022-04-01 2023-10-05 Zai Lab (Shanghai) Co., Ltd. Topical formulation comprising an il-17a binding molecule and uses thereof
TW202345903A (zh) 2022-04-22 2023-12-01 瑞士商月湖免疫治療股份有限公司 一種在對使用抗ｉｌ １７ａ／ｆ奈米抗體的治療有反應的個體中達到安全且持續的控制ｉｌ １７依賴型病狀的方法
CN115093483A (zh) * 2022-06-17 2022-09-23 国药中生生物技术研究院有限公司 Il-17ra融合蛋白、药物组合物、注射剂及其应用
TW202440614A (zh) 2022-12-23 2024-10-16 比利時商艾伯霖克斯公司 基於蛋白質的接合載體
EP4393948A1 (en) * 2022-12-28 2024-07-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Therapeutic vhh antibodies cross-neutralizing the il-17a and il-17f homodimers as well as the il-17af heterodimer
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
WO2024218708A2 (en) * 2023-04-18 2024-10-24 Moonlake Immunotherapeutics Ag Biomarker-based treatment and diagnostic methods for il-17-dependent conditions
CN116769027B (zh) * 2023-06-09 2023-12-01 康元医疗科技(大连)有限公司 一种抗il-17纳米抗体、多肽及其应用
WO2025049345A1 (en) 2023-08-25 2025-03-06 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof
CN117843776B (zh) * 2023-12-21 2024-08-30 北京贝来药业有限公司 抗体分子、核酸、制药用途及炎性疾病治疗方法
CN117843805B (zh) * 2023-12-29 2024-09-06 北京贝来药业有限公司 抗体分子、核酸分子、药物组合物以及应用
CN117843801B (zh) * 2023-12-29 2024-08-02 北京贝来药业有限公司 以白介素家族成员为靶点的新型抗体以及下游产品
CN117820481B (zh) * 2023-12-29 2025-02-14 北京贝来药业有限公司 新型抗体分子及其制药用途
CN117843804B (zh) * 2023-12-29 2024-08-20 北京贝来药业有限公司 单域抗体串联分子及其序列、产品、制备和应用
CN118206654B (zh) * 2024-03-05 2024-09-20 北京贝来药业有限公司 用于疾病治疗的新型抗体及其产品和应用
CN117866905B (zh) * 2024-03-12 2024-06-04 北京贝来药业有限公司 基于纳米抗体基因修饰的干细胞及其制备方法和产品
CN117866903B (zh) * 2024-03-12 2024-06-04 北京贝来药业有限公司 单域抗体修饰的干细胞及其在疾病治疗中用途
CN117860786B (zh) * 2024-03-12 2024-06-04 北京贝来药业有限公司 基因修饰间充质干细胞在多种疾病中的制药用途和诊断用途

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
WO1993023537A1 (en) 1992-05-08 1993-11-25 Creative Biomolecules Chimeric multivalent protein analogues and methods of use thereof
CA2137558A1 (en) 1992-07-17 1994-02-03 Wayne A. Marasco Method of intracellular binding of target molecules
PT656946E (pt) 1992-08-21 2001-12-28 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
AU7123494A (en) 1993-06-09 1995-01-03 Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno Process for producing fusion proteins comprising scfv fragments by a transformed mould
US6274711B1 (en) 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
US6091639A (en) 1993-08-27 2000-07-18 Kabushiki Kaisha Toshiba Non-volatile semiconductor memory device and data programming method
EP0745134A1 (en) 1994-02-22 1996-12-04 Danafarber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
PT839196E (pt) 1995-07-19 2005-09-30 Inst Genetics Llc Ctla-8 humana e utilizacoes de proteinas relacionadas com ctla-8
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
US6902735B1 (en) 1995-07-19 2005-06-07 Genetics Institute, Llc Antibodies to human IL-17F and other CTLA-8-related proteins
WO1998022141A2 (en) 1996-11-19 1998-05-28 Sangstat Medical Corporation Enhanced effects for hapten conjugated therapeutics
US20020177188A1 (en) 1998-05-15 2002-11-28 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
CN1203178C (zh) 1997-10-27 2005-05-25 尤尼利弗公司 多价抗原结合蛋白
BR9907241A (pt) 1998-01-26 2000-10-17 Unilever Nv Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo
ID26964A (id) 1998-02-19 2001-02-22 Xcyte Therapies Inc Komposisi dan metode untuk pengaturan pengaktifan limfosit
US6486303B1 (en) 1998-04-14 2002-11-26 University Of Medicine & Dentistry Of New Jersey Method for making hormone heterodimers
WO2000020593A1 (en) 1998-10-02 2000-04-13 Eli Lilly And Company Il-17 homolog nucleic acids, polypeptides, vectors, host cells, methods and uses thereof
GB9824632D0 (en) 1998-11-10 1999-01-06 Celltech Therapeutics Ltd Biological compounds
DE60013767T3 (de) 1999-01-19 2009-07-09 Unilever N.V. Verfahren zur herstellung von antikörperfragmenten
EP1053751A1 (en) 1999-05-17 2000-11-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods for treating cell proliferation disorders
ATE519847T1 (de) 1999-12-23 2011-08-15 Genentech Inc Il-17-homologe polypeptide und ihre therapeutische verwendung
WO2001045746A2 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20030199043A1 (en) 2000-04-12 2003-10-23 Ballance David J. Albumin fusion proteins
CA2441903C (en) 2000-05-26 2012-07-31 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
WO2001090190A2 (en) 2000-05-26 2001-11-29 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
US6741957B1 (en) 2000-07-21 2004-05-25 Daimlerchrysler Corporation Analytical tire model for vehicle durability and ride comfort analysis
WO2002056910A1 (en) 2001-01-17 2002-07-25 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
AU2002242142A1 (en) 2001-02-09 2002-08-28 Johns Hopkins University A cytokine related structurally to il-17
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
JP4303105B2 (ja) 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
JP2004538324A (ja) 2001-08-03 2004-12-24 メディカル リサーチ カウンシル 細胞内抗体
EP1433793A4 (en) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
KR100599789B1 (ko) 2001-12-03 2006-07-12 삼성에스디아이 주식회사 방열효율이 향상된 플라즈마 디스플레이 장치 및 그 제조방법
WO2003050531A2 (en) 2001-12-11 2003-06-19 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
JP4323317B2 (ja) 2001-12-21 2009-09-02 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー（ヴェーイーベー・ヴェーゼットウェー） 可変領域配列のクローニング方法
WO2003055527A2 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
US20080241166A1 (en) 2002-06-28 2008-10-02 Domantis Limited Ligands that bind a receptor
DE60305919T2 (de) 2002-06-28 2007-01-18 Domantis Limited, Cambridge Dual-specifische liganden mit erhöhter halbwertszeit
US7004940B2 (en) 2002-10-10 2006-02-28 Ethicon, Inc. Devices for performing thermal ablation having movable ultrasound transducers
EP1558646A2 (en) 2002-11-08 2005-08-03 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses thereof
EP2258392A1 (en) 2002-11-08 2010-12-08 Ablynx N.V. Method of administering therapeutic polypeptides
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
US7993864B2 (en) 2002-12-03 2011-08-09 Ucb Pharma S.A. Assay for identifying antibody producing cells
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
US7432330B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
US9028816B2 (en) 2003-01-10 2015-05-12 Ablynx N.V. Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
PL1639011T3 (pl) 2003-06-30 2009-05-29 Domantis Ltd Pegilowane przeciwciała jednodomenowe (dAb)
PL1641822T3 (pl) 2003-07-08 2013-10-31 Genentech Inc Heterologiczne polipeptydy IL-17 A/F i ich zastosowania terapeutyczne
EP1656128A4 (en) 2003-08-12 2007-02-28 William M Yarbrough SINGLE ACNE TREATMENT AND METHOD OF USE
US20060263353A1 (en) 2003-08-20 2006-11-23 Lawson Alastair D G Methods for obtaining antibodies
US20050279676A1 (en) 2004-06-21 2005-12-22 Izzy Zuhair A Fluid filter assembly for a dispensing faucet
US7882839B2 (en) 2004-06-25 2011-02-08 Ambis Jr Edward J Custom mouthguard
US20060008601A1 (en) 2004-06-25 2006-01-12 Zeik Douglas B Flexible laminate having an integrated pressure release valve
HUE034335T2 (en) 2004-07-22 2018-02-28 Kingdon Craig R binding molecule
CN100396019C (zh) 2004-07-31 2008-06-18 华为技术有限公司 移动终端数据源模拟方法
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
WO2006040154A2 (en) 2004-10-14 2006-04-20 Dublin City University Prokaryotic two hybrid system
GB0425569D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
MY142617A (en) 2004-12-23 2010-12-15 Domantis Ltd Dual specific ligands with increased serum half-life
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
MX2007009811A (es) 2005-02-14 2007-09-07 Wyeth Corp Anticuerpos para interleucina-17f y otros antagonistas de la senalizacion de il 17f, y sus usos.
CN101248087B (zh) 2005-05-18 2012-09-26 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
EP3415535B1 (en) 2005-05-20 2020-12-09 Ablynx N.V. Improved nanobodies tm for the treatment of aggregation-mediated disorders
US20090252681A1 (en) 2005-10-11 2009-10-08 Ablynx N.V. Nanobodies and Polypeptides Against EGFR and IGF-IR
JP2009511032A (ja) 2005-10-11 2009-03-19 アブリンクス エン．ヴェー． Ｅｇｆｒおよびｉｇｆ−ｉｒに対するナノボディおよびポリペプチド
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
WO2007112940A2 (en) 2006-03-31 2007-10-11 Ablynx N.V. Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same
EP2010568A1 (en) 2006-04-14 2009-01-07 Ablynx N.V. Dp-78-like nanobodies
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
WO2008000279A1 (en) 2006-06-26 2008-01-03 Aida Centre, S.L. Blister package integrating rfid based tags
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
AU2007293614A1 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
US20100129368A9 (en) 2006-10-11 2010-05-27 Ablynx N.V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the pH, compounds comprising the same, and uses thereof
GB0620729D0 (en) * 2006-10-18 2006-11-29 Ucb Sa Biological products
US20080267949A1 (en) 2006-12-05 2008-10-30 Ablynx N.V. Peptides capable of binding to serum proteins
SG178789A1 (en) 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
WO2008118930A1 (en) 2007-03-26 2008-10-02 Zymogenetics, Inc. Soluble il-17ra/rc fusion proteins and related methods
WO2009023386A2 (en) 2007-07-06 2009-02-19 Trubion Pharmaceuticals, Inc. Binding peptides having a c-terminally disposed specific binding domain
WO2009068627A2 (en) 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
CN101932593B (zh) 2008-01-29 2014-08-20 埃博灵克斯股份有限公司 稳定蛋白和多肽的方法
CA2721202A1 (en) 2008-04-17 2009-10-22 Hilde Adi Pierrette Revets Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
NZ600584A (en) 2008-05-05 2014-05-30 Novimmune Sa Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof
CA2724208C (en) 2008-05-16 2018-02-06 Ablynx Nv Amino acid sequences directed against cxcr4 and other gpcrs and compounds comprising the same
US8790642B2 (en) * 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
MY153893A (en) 2008-09-29 2015-04-15 Roche Glycart Ag Antibodies against human il17 and uses thereof
EP3235509A1 (en) 2009-03-05 2017-10-25 AbbVie Inc. Il-17 binding proteins
DK2982690T3 (da) 2009-04-30 2021-04-12 Ablynx Nv Fremgangsmåde til fremstilling af domæne-antistoffer
SG175276A1 (en) 2009-05-05 2011-11-28 Novimmune Sa Anti-il-17f antibodies and methods of use thereof
WO2010142551A2 (en) * 2009-06-12 2010-12-16 Ablynx N.V. Single variable domain (vhh) antibodies to cytokines of the il-17 receptor family
ES2728115T3 (es) 2009-10-30 2019-10-22 Janssen Biotech Inc Antagonistas de IL-17A
SG10201604093XA (en) 2010-01-15 2016-07-28 Kirin Amgen Inc Antibody formulation and therapeutic regimens
US8965476B2 (en) * 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
RU2591083C2 (ru) 2010-10-08 2016-07-10 Новартис Аг Способы лечения псориаза с использованием антагонистов il-17
EP3912640B1 (en) 2010-11-05 2025-03-05 Novartis AG Pharmaceutical compositions comprising secukinumab
SG191906A1 (en) 2011-01-14 2013-08-30 Ucb Pharma Sa Antibody molecules which bind il-17a and il-17f
TWI439451B (zh) 2011-03-24 2014-06-01 Hoffmann La Roche 雜環胺衍生物
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
EP2771361A1 (en) 2011-10-24 2014-09-03 AbbVie Inc. Bispecific immunobinders directed against tnf and il-17
WO2013150043A1 (en) 2012-04-05 2013-10-10 F. Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
AR090626A1 (es) 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos
TWI632159B (zh) 2013-02-08 2018-08-11 諾華公司 抗－ｉｌ－１７ａ抗體及其於治療自體免疫及發炎病症之用途
CL2015001213A1 (es) 2015-05-07 2015-07-10 Pontificia Universidad Católica De Chile Método ex vivo para predecir respuesta a un tratamiento inmunomodulador en pacientes con enfermedad inflamatoria, el cual comprende la cuantificación de las razones entre las concentraciones de citoquinas seleccionadas de ifn-gamma/il-17f, il17f/il-10, il-17f/ifn-gamma e il-10/il17f; y kit para llevar a cabo el método.

Also Published As

Publication number Publication date
US20140314743A1 (en) 2014-10-23
US20210130452A1 (en) 2021-05-06
JP7093380B2 (ja) 2022-06-29
JP2020193195A (ja) 2020-12-03
SI2705058T1 (en) 2018-04-30
WO2012156219A1 (en) 2012-11-22
US20220195031A1 (en) 2022-06-23
CL2013003090A1 (es) 2014-10-10
JP2014516945A (ja) 2014-07-17
MX2013012844A (es) 2013-11-20
WO2012156219A9 (en) 2013-04-18
NZ616761A (en) 2016-01-29
HUE037225T2 (hu) 2018-08-28
US20190100584A1 (en) 2019-04-04
MY167231A (en) 2018-08-14
PH12013502234A1 (en) 2014-01-06
BR112013028407B1 (pt) 2021-11-23
SG10201606409TA (en) 2016-09-29
EP3363815A1 (en) 2018-08-22
IL228813A0 (en) 2013-12-31
LT2705058T (lt) 2018-04-10
PT2705058T (pt) 2018-03-20
JP2024122989A (ja) 2024-09-10
CN107098971A (zh) 2017-08-29
SG194632A1 (en) 2013-12-30
AU2012257942A8 (en) 2015-09-10
JP2022137058A (ja) 2022-09-21
CA2834907C (en) 2023-03-07
US11773159B2 (en) 2023-10-03
AU2012257942B2 (en) 2015-08-20
US10829552B2 (en) 2020-11-10
EA201391632A1 (ru) 2014-07-30
ES2662371T3 (es) 2018-04-06
AU2012257942A1 (en) 2013-05-02
EP2705058A1 (en) 2014-03-12
KR20140132661A (ko) 2014-11-18
EA035973B9 (en) 2021-03-30
CA2834907A1 (en) 2012-11-22
EP4105231A1 (en) 2022-12-21
JP6768027B2 (ja) 2020-10-14
JP6628965B2 (ja) 2020-01-15
EA035973B1 (ru) 2020-09-08
IL228813B (en) 2018-07-31
DK2705058T3 (en) 2018-03-05
KR102083230B1 (ko) 2020-03-02
US10017568B2 (en) 2018-07-10
CN107098971B (zh) 2020-07-10
AU2012257942A2 (en) 2014-06-05
AU2012257942B8 (en) 2015-09-17
JP2018154628A (ja) 2018-10-04
HRP20180380T1 (hr) 2018-04-06
BR112013028407A2 (pt) 2016-11-29
EP2705058B1 (en) 2018-01-10
CN103717618B (zh) 2016-12-07
CN103717618A (zh) 2014-04-09

Similar Documents

Publication Publication Date Title
UA117218C2 (uk) Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
CO7461145A2 (es) Péptidos y composiciones para el tratamiento de daño articular
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
CL2009000650A1 (es) Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras
CL2015002301A1 (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxílico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c.
BR112013020500A8 (pt) anticorpo isolado, recombinante ou purificado
UY37018A (es) Inhibidores bicíclicos de pad4
CL2007003666A1 (es) Compuestos derivados del acido nicotinico; composicion farmaceutica que comprende a dichos compuestos; combinacion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis, esclerosis multiple, psoriasis, entre otras.
NZ627980A (en) Pharmaceutical compositions containing dimethyl fumarate
PH12018500409A1 (en) New bicyclic compounds as dual atx/ca inhibitors
UA117011C2 (uk) Фармацевтичний склад омекамтиву мекарбілу і спосіб його застосування
UA118167C2 (uk) Пептид та його застосування
BR112015023207A8 (pt) composições de ci-inh e métodos para prevenção e tratamento de desordens associadas à deficiência de inibidor de c1 esterase.
UA117096C2 (uk) Поліпептид, що зв'язується з c5 комплементу людини
MY181068A (en) Recombinant microorganism for improved production of fine chemicals
UA108636C2 (xx) Пептид
MX373320B (es) Compuestos inhibidores de pde2.
PH12015500169A1 (en) Prediction of treatment response to jak/stat inhibitor
UA116889C2 (uk) Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc)
EA201491496A1 (ru) Ингибиторы c-концевого домена hsp90
MX2020013096A (es) Rutas semi-sinteticas para compuestos organicos.
GB201118201D0 (en) Novel peptides
MX2020012065A (es) Compuestos de ciclopentano.
EP2569327A4 (en) EIF4E BINDING PEPTIDES
PH12015500815A1 (en) Treatment of scleroderma using an inhibitor of cbp\catenin